Alfredo Mauriello, Adriana Correra, Gerardo Elia Del Vecchio, Martina Grieco, Arianna Amata, Pierpaolo Di Micco, Egidio Imbalzano, Mariano Paternoster, Antonia Ascrizzi, Vincenzo Quagliariello, Nicola Maurea, Francesco Giallauria, Antonello D'Andrea, Vincenzo Russo
{"title":"心力衰竭和宽QRS:临床和药理学观点。","authors":"Alfredo Mauriello, Adriana Correra, Gerardo Elia Del Vecchio, Martina Grieco, Arianna Amata, Pierpaolo Di Micco, Egidio Imbalzano, Mariano Paternoster, Antonia Ascrizzi, Vincenzo Quagliariello, Nicola Maurea, Francesco Giallauria, Antonello D'Andrea, Vincenzo Russo","doi":"10.3390/biomedicines13061462","DOIUrl":null,"url":null,"abstract":"<p><p>Heart failure (HF) is a highly prevalent cardiovascular clinical syndrome. Health care spending on HF treatment is high. Therefore, its treatment has generated a great deal of interest in pharmacological research in recent years. Recent guidelines have introduced several molecules for the treatment of HF that have demonstrated safety, and above all, efficacy. One of the worst aspects of HF is ventricular dyssynchrony (VD) with a wide QRS interval. Currently, the cornerstone of VD therapy is cardiac resynchronization therapy (CRT). Our comprehensive review aims to analyze the effects of new molecules on QRS width and understand whether these molecules can provide benefits.</p>","PeriodicalId":8937,"journal":{"name":"Biomedicines","volume":"13 6","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12190266/pdf/","citationCount":"0","resultStr":"{\"title\":\"Heart Failure and Wide QRS: Clinical and Pharmacological Perspectives.\",\"authors\":\"Alfredo Mauriello, Adriana Correra, Gerardo Elia Del Vecchio, Martina Grieco, Arianna Amata, Pierpaolo Di Micco, Egidio Imbalzano, Mariano Paternoster, Antonia Ascrizzi, Vincenzo Quagliariello, Nicola Maurea, Francesco Giallauria, Antonello D'Andrea, Vincenzo Russo\",\"doi\":\"10.3390/biomedicines13061462\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Heart failure (HF) is a highly prevalent cardiovascular clinical syndrome. Health care spending on HF treatment is high. Therefore, its treatment has generated a great deal of interest in pharmacological research in recent years. Recent guidelines have introduced several molecules for the treatment of HF that have demonstrated safety, and above all, efficacy. One of the worst aspects of HF is ventricular dyssynchrony (VD) with a wide QRS interval. Currently, the cornerstone of VD therapy is cardiac resynchronization therapy (CRT). Our comprehensive review aims to analyze the effects of new molecules on QRS width and understand whether these molecules can provide benefits.</p>\",\"PeriodicalId\":8937,\"journal\":{\"name\":\"Biomedicines\",\"volume\":\"13 6\",\"pages\":\"\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2025-06-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12190266/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomedicines\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://doi.org/10.3390/biomedicines13061462\",\"RegionNum\":3,\"RegionCategory\":\"工程技术\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedicines","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3390/biomedicines13061462","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
Heart Failure and Wide QRS: Clinical and Pharmacological Perspectives.
Heart failure (HF) is a highly prevalent cardiovascular clinical syndrome. Health care spending on HF treatment is high. Therefore, its treatment has generated a great deal of interest in pharmacological research in recent years. Recent guidelines have introduced several molecules for the treatment of HF that have demonstrated safety, and above all, efficacy. One of the worst aspects of HF is ventricular dyssynchrony (VD) with a wide QRS interval. Currently, the cornerstone of VD therapy is cardiac resynchronization therapy (CRT). Our comprehensive review aims to analyze the effects of new molecules on QRS width and understand whether these molecules can provide benefits.
BiomedicinesBiochemistry, Genetics and Molecular Biology-General Biochemistry,Genetics and Molecular Biology
CiteScore
5.20
自引率
8.50%
发文量
2823
审稿时长
8 weeks
期刊介绍:
Biomedicines (ISSN 2227-9059; CODEN: BIOMID) is an international, scientific, open access journal on biomedicines published quarterly online by MDPI.